Menu
Recruiting NCT06693986

Adenovirus (RGDCRAdCOX2F)

Phase I Interventional Adenocarcinoma of Pancreas

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Replicative Adenovirus Vector (RGDCRAdCOX2F).
Who it may be relevant to
Registry conditions: Adenocarcinoma of Pancreas. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Phase I Study of a Tropism Modified Conditionally Replicative Adenovirus Vector (RGDCRAdCOX2F) for Endoscopic, Direct-Tumor Delivery in Pancreatic Adenocarcinoma

Overview

This is a single center, Phase I dose finding study of a single direct tumor injection of an RGD modified conditionally replicative adenovirus (RGDCRAdcox2F) in persons with adenocarcinoma of the pancreas. The study is designed to determine the MTD of RGDCRAdCOX2F that corresponds to the maximum desired toxicity of ≤ 20%.

Interventions

  • Biological Replicative Adenovirus Vector (RGDCRAdCOX2F)
    RGDCRAdcox2F (RGD) is a "local" product and is provided through this study.

Primary outcome measures

  • Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

  • Histologically documented pancreatic adenocarcinoma that is confined to the pancreas and regional lymph nodes after staging by CT or MRI and endoscopic ultrasound.
  • One prior line of therapy is permitted (i.e. neo-adjuvant therapy); however, at least 4 weeks must have elapsed between the last dose of drug and the injection of RGDCRAdCOX2F.
  • Must be able to tolerate esophagogastroduodenoscopy (EGD) and the tumor must be accessible by endoscopic ultra sound. Participants will be excluded if obtaining biopsies are deemed unsafe or not feasible.
  • Age 18 years of age or older at the time of consent
  • Normal cardiac and pulmonary function based on history and physical exam
  • Participants with partners of childbearing potential must be willing to use at least two forms of effective birth control (one form must be a barrier method) for at least 1 month after Day 1.

Exclusion criteria

  • Pregnant or breastfeeding. Persons of child-bearing potential must have a negative pregnancy test (serum or urine) with 14 days of study enrollment.
  • Other pancreatic malignancies (e.g., neuroendocrine tumors and mucinous cystic) and adenocarcinomas of the ampulla, bile ducts, and duodenum.
  • Tumors in mucosal regions or close to an airway, major blood vessel, or spinal cord that in the opinion of the enrolling investigator could cause occlusion or compression in the case of tumor swelling or erosion into a major vessel in the case of necrosis.
  • Known history of human immunodeficiency virus (HIV) infection
  • Known history of or active acute or chronic active hepatitis B or C infection
  • Serious concurrent infection or medical illness, which in the enrolling investigator's opinion would jeopardize the ability of the participant to receive the treatment outlined in this protocol with reasonable safety.
  • Requires immunosuppression ≥10mg/day of prednisone for more than

1 week.

  • History of or active known or suspected autoimmune disease, or a syndrome that requires systemic or immunosuppressive agents.
  • Disease beyond the regional lymph nodes
  • Active diffuse pancreatitis
  • Active inflammatory conditions
  • Prior gastrojejunostomy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Sequential
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 1 center
  • Masonic Cancer Center — Minneapolis

Identifiers

NCT: NCT06693986 · 2022LS030

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗